Compare GAIA & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | INKT |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 70.6M |
| IPO Year | 1999 | 2021 |
| Metric | GAIA | INKT |
|---|---|---|
| Price | $3.08 | $12.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 53.9K | 46.5K |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,500,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $2.45 | $6.66 |
| 52 Week High | $6.39 | $76.00 |
| Indicator | GAIA | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 51.98 |
| Support Level | $2.98 | $10.88 |
| Resistance Level | $3.46 | $12.58 |
| Average True Range (ATR) | 0.12 | 1.04 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 100.00 | 30.79 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.